Emcure Pharmaceuticals Ltd
Emcure Pharmaceuticals Q2 Results 2026 (FY27) investor presentation: Revenue & Margins
Q2 FY27 investor presentation: what the company reported on revenue, margins and capex.
Guidance rank: #47 of 84 in Pharmaceuticals & Biotechnology
See the sector's top 10 — free with your mobile number.
Emcure Pharmaceuticals Ltd Q2 FY27 key numbers
- Revenue
- Q2FY27 Revenue from Operations: INR 28,205 Mn, up 24.3% YoY.
As stated in Emcure Pharmaceuticals Ltd's Q2 FY27 investor presentation · published 3 Nov 2026. Reported figures, not investment advice.
Based on Emcure Pharmaceuticals Ltd's Q2 FY27 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.
The short version
Q2FY27 Revenue from Operations: INR 28,205 Mn, up 24.3% YoY (Page 9). Q2FY27 EBITDA: INR 5,748 Mn, 30.9% YoY growth, with an EBITDA margin of 20.4% (up 103 bps YoY) - Q2FY27 Profit After Tax (PAT): INR 3,251 Mn, 29.3% YoY growth, with a PAT margin of 11.5% (up 45 bps
From Emcure Pharmaceuticals Ltd's Q2 FY27 earnings-call transcript · updated 3 Nov 2026.
Revenue & Sales Performance
- Q2FY27 Revenue from Operations: INR 28,205 Mn, up 24.3% YoY (Page 9).
- Domestic revenue: INR 11,553 Mn, up 12.0% YoY (Page 9).
- International revenue: INR 16,652 Mn, up 34.5% YoY (Page 9).
- RoW (Rest of World) revenue: INR 6,297 Mn, up 41.1% YoY (Page 9).
- Europe revenue: INR 6,043 Mn, up 36.0% YoY (Page 9).
- Canada revenue: INR 4,312 Mn, up 24.0% YoY (Page 9).
2 more points from Emcure Pharmaceuticals Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Emcure Pharmaceuticals Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Emcure Pharmaceuticals Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- The presentation mentions a "strong orderbook and continued scale up of existing portfolio" in the RoW (Rest of World) segment, particularly related to ARV (Anti retroviral) products (Page 8).
- It highlights momentum driven by this strong orderbook and product portfolio scale-up in the international business.
- The term “orderbook” is only explicitly referenced in relation to RoW ARV business growth outlook visibility.
Emcure Pharmaceuticals Ltd — Quarterly revenue & net profit
Q2 FY27 figures are not in this chart yet. Latest shown: Mar 2026 (Q4 FY26). The Q2 FY27 numbers from the filing are in the analysis on this page.
Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹2.5K Cr, net profit ₹244 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Emcure Pharma's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Neuland Laboratories (Q2 FY27)
Q2FY27 Total Income (revenue) was ₹457.2 crore, down 11.4% year-on-year (YoY) from Q2FY26. Key investor presentation takeaways from Neuland Laboratories Ltd's Q
- Hikal (Q2 FY27)
Consolidated Revenue Q2FY27:** ₹434 crores, up 36% YoY from ₹319 crores in Q2FY26 (Page 9) . Key investor presentation takeaways from Hikal Ltd's Q2 FY27 invest
- Kopran (Q2 FY27)
9,335 lakhs (~79% increase) . Key investor presentation takeaways from Kopran Ltd's Q2 FY27 investor presentation — and how it ranks against sector peers.
- SPARC (Q2 FY27)
Revenue from operations for the quarter ended September 30, 2026, is ₹3,003 lakhs, up from ₹786 lakhs in the quarter ended September 30, 2025. Key results state
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Emcure Pharmaceuticals Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Emcure Pharmaceuticals Ltd Q2 FY27 results?
Q2FY27 Revenue from Operations: INR 28,205 Mn, up 24.3% YoY (Page 9). Q2FY27 EBITDA: INR 5,748 Mn, 30.9% YoY growth, with an EBITDA margin of 20.4% (up 103 bps YoY) - Q2FY27 Profit After Tax (PAT): INR 3,251 Mn, 29.3% YoY growth, with a PAT margin of 11.5% (up 45 bps
What is Emcure Pharmaceuticals Ltd share price analysis?
Emcure Pharmaceuticals Ltd currently shows a neutral. The stock trades at a P/E of 34.7 with a market cap of ₹35,732 Cr. Investors should review the full earnings analysis for detailed insights.
Is Emcure Pharmaceuticals Ltd planning capital expenditure?
Capex spent in H1 FY27 was INR 2,877 Mn, up from INR 1,700 Mn in H1 FY26 (Page 11).
Keep Emcure Pharmaceuticals Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.